Research ArticleOriginal Article
Open Access

Clinical and biochemical profile of Guillain Barré Syndrome in Pakistan

Rashid Iqbal, Muhammad J. Asad, Muhammad B. Shah, Raja T. Mahmood and Saima Siddiqi
Neurosciences Journal July 2021, 26 (3) 242-247; DOI: https://doi.org/10.17712/nsj.2021.3.20200178

Article Figures & Data

Tables

  • Table 1.

    - Comparison of IL-17 levels between cases and controls.

    SubjectsnMeanSDMinMaxP-value
    GBS variants
    AIDP5218.03854.2677211.326.567
    AMAN3918.88723.9087112.427.8 
    AMSAN1718.64124.2855912.425.5 
    MFS221.451.4849220.422.5 
    Cases
    GBS11018.49454.1088111.327.8<.001
    Controls
    HC13010.662.095345.313.5 

    • Min - Minimum, Max - Maximum, GBS - Guillain Barre Syndrome, AIDP -Acute inflammatory demyelinating polyneuropathy, AMAN - Acute motor axonal neuropathy, MFS - Miller Fischer Syndrome, n - Number of subjects, SD - Standard Deviation, HC - Healthy controls without disease

  • Table 2.

    - The CSF findings in GBS patients significant difference of CSF protein between AIDP and AMSAN, p=0.001, followed by AIDP and AMAN, p=0.015

    GBS variant (%)MeanSDMinimumMaximumP- value
    AIDP (47.27)145.30839.911438199 
    AMAN (35.45)119.89553.769830198 
    AMSAN (15.45)97.41260.7547301970.002
    MFS (1.81)92.53.53559095 
    Total (100)127.93551.289830199 

    • AIDP - acute inflammatory demyelinating polyneuropathy, AMAN - Acute motor axonal neuropathy, AMSAN - Acute motor sensory axonal neuropathy, MFS - Miller Fischer syndrome, CSF - Cerebrospinal fluid, GBS - Guillain-Barré syndrome, AIDP - Acute inflammatory demyelinating polyneuropathy

  • Table 3.

    - Clinical parameters and characteristics of GBS patients.

    ParametersAIDPAMANAMSANMFSTotalP- value
    Sex, n (%)
    Male Female29 (55.76) 23 (44.23)27 (69.23)12 (30.76)16 (94.11) 1 (5.88)2 (100)74 (67.27) 36 (32.72).021
    Age, years
    Mean (SD)41.27 (16.38)36.33(15.35)39.59(16.56)33 (18.38)39.11 (16.0).495
    Hb, mean (SD)
    Male14.6)0.86}14.9(1.04)14.8 (1.25)15.4(0.35)14.83(1.01).597
    Female10.9(1.20)10.7(1.23)11.2 (0.85) 10.88(1.18).647
    LFT, mean (SD)
    T. Bil0.73(0.36)0.73(0.38)0.83 (0.39)0.55(0.70)0.74 (0.37).674
    ALT28 (11.4)31 (13.3)30 (17.4)43 (12.7)30 (13.1).416
    RFT, mean (SD)
    Urea30 (11.1)33 (13.7)32 (8.1)29 (0.70)31 (11.6).467
    Creat0.63(0.16)0.67(0.16)0.68 (0.19)0.83(0.07)0.66 (0.17).314
    Lipid, mean (SD)
    Chol187 (51)181 (46)190 (58)194 (55)186 (50).171
    Tg133 (32)139 (33)132 (38)117 (3.5)135 (33).501
    Antecedent infection,n
    (%)GI36 (69.23)16 (41.0)6 (35.29) 59 (53.63) 
    URTI9 (17.30)5 (12.82)3 (17.64)1 (50)17 (15.45).013
    Fever1 (1.92)10 (25.64)2 (11.76) 13 (11.81) 
    None6 (11.53)8 (20.51)6 (35.29)1 (50)21 (19.0) 
    Seasonal trends, n (%)
    Summer11 (21.15)8 (20.51)1 (5.88) 20 (18.19) 
    Winter16 (30.76)11 (28.20)  27 (24.54)<.001
    Autumn 10 (25.64)6 (35.29) 16 (14.54) 
    Spring25 (48.07)9 (23.07)10 58.82)2 (100)44 (40) 
    Residence, n (%)
    Urban35 (67.30)4 (10.25)1 (5.88) 40 (36.3) 
    Rural17 (32.69)35 (89.74)16 (94.11)2 (100)70 (63.6)<.001
    Clinical features, n (%)
    Respiratory distress7 (13.4)6 (15.3)3 (17.6) 9 (8.1) 
    Walking difficulty31 (59.6)24 (61.5)10 (58.8)1 (50)70 (63.6) 
    Ascending weakness38 (73.0)29 (74.3)12 (70.5)1 (5082 (74.5) 
    Tingling29 (55.7)21 (53.84)9 (52.9)1 (50)71 (64.5)<.001
    Hb - Hemoglobin, T.Bil - Total Bilirubin, Chol - Cholesterol, Tg - Triglyceride, creat - creatinine, GI - Gastrointestinal infection, URTI - Upper respiratory infection, RFT - RenalFunction Test, AMSAN - Acute motor sensory axonal neuropathy, LFT - Liver Funcion Test
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section